5210 related articles for article (PubMed ID: 427824)
1. Experimental antitumor activity of aminoanthraquinones.
Johnson RK; Zee-Cheng RK; Lee WW; Acton EM; Henry DW; Cheng CC
Cancer Treat Rep; 1979 Mar; 63(3):425-39. PubMed ID: 427824
[TBL] [Abstract][Full Text] [Related]
2. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
3. Levodopa and dopamine analogs: dihydroxy and trihydroxybenzylamines as novel quinol antitumor agents in experimental leukemia in vivo.
Wick MM
Cancer Treat Rep; 1981; 65(9-10):861-7. PubMed ID: 7273019
[TBL] [Abstract][Full Text] [Related]
4. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
5. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.
Wallace RE; Murdock KC; Angier RB; Durr FE
Cancer Res; 1979 May; 39(5):1570-4. PubMed ID: 427798
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of bizelesin in mice.
Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
[TBL] [Abstract][Full Text] [Related]
9. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
10. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
Finch RA; Shyam K; Penketh PG; Sartorelli AC
Cancer Res; 2001 Apr; 61(7):3033-8. PubMed ID: 11306484
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
Fujimoto S; Ogawa M
Cancer Chemother Pharmacol; 1982; 8(2):157-62. PubMed ID: 7105379
[TBL] [Abstract][Full Text] [Related]
14. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Johnson RK; Inouye T; Goldin A; Stark GR
Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
[TBL] [Abstract][Full Text] [Related]
16. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
Dawson KM
Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
[TBL] [Abstract][Full Text] [Related]
17. New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity.
Regenass U; Caravatti G; Mett H; Stanek J; Schneider P; Müller M; Matter A; Vertino P; Porter CW
Cancer Res; 1992 Sep; 52(17):4712-8. PubMed ID: 1511437
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors.
Furusawa S; Mian AM
Cancer Treat Rep; 1987 May; 71(5):441-6. PubMed ID: 3567967
[TBL] [Abstract][Full Text] [Related]
19. Biological characterization of a novel antitumor quinolone.
Clement JJ; Burres N; Jarvis K; Chu DT; Swiniarski J; Alder J
Cancer Res; 1995 Feb; 55(4):830-5. PubMed ID: 7850797
[TBL] [Abstract][Full Text] [Related]
20. Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents.
Corbett TH; Roberts BJ; Trader MW; Laster WR; Griswold DP; Schabel FM
Cancer Treat Rep; 1982 May; 66(5):1187-200. PubMed ID: 7083221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
